Aarti Drugs · NSE: AARTIDRUGS · BSE: 524348
Q1 FY21 results · Apr–Jun 2020
Aarti Drugs reported revenue from operations of ₹544.67 crore (up 34.3% from Q1 FY20) and net profit of ₹85.45 crore (up 280.6% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 544.67 | 405.43 | +34.3% | 449.64 | +21.1% |
| Other income | 1.26 | 0.06 | 21x | 0.99 | +27.3% |
| Total income | 545.93 | 405.49 | +34.6% | 450.63 | +21.1% |
| Profit before tax | 116.28 | 33.63 | +245.8% | 60.72 | +91.5% |
| Net profit for the period | 85.45 | 22.45 | +280.6% | 58.86 | +45.2% |
| EPS, basic (₹) | 36.67 | 9.56 | +283.6% | 25.26 | +45.2% |
| Net margin (%) | 15.7 | 5.5 | 13.1 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 475.55 | 370.02 | +28.5% | 406.57 | +17.0% |
| Other income | 1.24 | 0.10 | 12x | 0.62 | +100.0% |
| Total income | 476.79 | 370.12 | +28.8% | 407.19 | +17.1% |
| Profit before tax | 99.03 | 32.32 | +206.4% | 57.36 | +72.6% |
| Net profit for the period | 73.03 | 21.57 | +238.6% | 56.56 | +29.1% |
| EPS, basic (₹) | 31.34 | 9.19 | +241.0% | 24.28 | +29.1% |
| Net margin (%) | 15.4 | 5.8 | 13.9 |
Consolidated
- Filed with BSE
- 27 Jul 2020, 13:19 IST
- Board meeting
- 25 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 27 Jul 2020, 13:19 IST
- Board meeting
- 25 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Audited
- Source
- XBRL filing on BSE